Regular Analgesic Use Increases Hearing Loss in Men
According to New Study Published in The American Journal of Medicine
New York, NY, 1 March 2010 – In a study published in the March 2010 issue of The American Journal of Medicine, researchers determined that regular use of aspirin, acetaminophen and non-steroidal anti-inflammatory drugs (NSAIDs) increases the risk of hearing loss in men, particularly in younger men, below age 60.
Hearing loss is the most common sensory disorder in the US, afflicting over 36 million people. Not only is hearing loss highly prevalent among the elderly, but approximately one third of those aged 40-49 years already suffer from hearing loss. Even mild hearing loss can compromise the ability to understand speech in the presence of background noise or multiple speakers, leading to social isolation, depression, and poorer quality of life.
Investigators from Harvard University, Brigham and Women’s Hospital, Vanderbilt University and the Massachusetts Eye and Ear Infirmary, Boston looked at factors other than age and noise that might influence the risk of hearing lose. Aspirin, acetaminophen, and ibuprofen are the 3 most commonly used drugs in the US. The ototoxic effects of aspirin are well known and the ototoxicity of NSAIDs has been suggested, but the relation between acetaminophen and hearing loss has not been examined previously. The relationship between these drugs and hearing loss is an important public health issue.
Study participants were drawn from the Health Professionals Follow-up Study, which tracked over 26,000 men every 2 years for 18 years. A questionnaire determined analgesic use, hearing loss and a variety of physiological, medical and demographic factors.
For aspirin, regular users under 50 and those aged 50-59 years were 33% more likely to have hearing loss than were nonregular users, but there was no association among men aged 60 years and older. For NSAIDs, regular users aged under 50 were 61% more likely, those aged 50-59 were 32% more likely, and those aged 60 and older were 16% more likely to develop hearing loss than nonregular users of NSAIDs. For acetaminophen, regular users aged under 50 were 99% more likely, regular users aged 50-59 were 38% more likely, and those aged 60 and older were 16% more likely to have hearing loss than nonregular users of acetaminophen.
Writing in the article, Sharon G. Curhan, MD, ScM, Channing Laboratory, Department of Medicine, Brigham and Women’s Hospital, Boston, and colleagues state, “Regular use of analgesics, specifically aspirin, NSAIDs, and acetaminophen, might increase the risk of adult hearing loss, particularly in younger individuals. Given the high prevalence of regular analgesic use and health and social implications of hearing impairment, this represents an important public health issue.”
The article is “Analgesic Use and the Risk of Hearing Loss in Men” by Sharon G. Curhan, MD, ScM, Roland Eavey, MD, Josef Shargorodsky, MD, Gary C. Curhan, MD, ScD. It appears in The American Journal of Medicine, Volume 123, Issue 3 (March 2010) published by Elsevier.
Full text of the article is available upon request. Contact Pamela Poppalardo at 732-238-3628 or firstname.lastname@example.org to obtain a copy. To schedule an interview with Sharon G. Curhan, MD, ScM, contact Lori J. Shanks, Senior Media Relations Specialist, Public Affairs, Brigham and Women's Hospital, 617-534-1604 (office), 617-459-2111 (cell), email@example.com.
About The American Journal of Medicine
The American Journal of Medicine, known as the “Green Journal,” is one of the oldest and most prestigious general internal medicine journals published in the United States. It is ranked 11th out of 100 General and Internal Medicine titles according to the 2007 Journal Citation Reports© published by Thomson Reuters.
AJM, the official journal of The Association of Professors of Medicine, a group comprised of chairs of departments of internal medicine at 125-plus U.S. medical schools, publishes peer-reviewed, original scientific studies that have direct clinical significance. The information contained in this article in The American Journal of Medicine is not a substitute for medical advice or treatment, and the Journal recommends consultation with your physician or healthcare professional. AJM is published by Elsevier.
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence,and ClinicalKey—and publishes over 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.
The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
+1 732 238 3628